Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

PFS did not differ between ribociclib and palbociclib ( p = 0.192); OS favored ribociclib at borderline significance ( p = 0.050), but this was not confirmed in Cox regression.

also in 7,017 other papers

Outcomes appeared to differ between BRCA1 and BRCA2 carriers, with BRCA1 carriers showing numerically longer progression-free survival, although this difference did not reach statistical significance. These findings suggest that the BRCA mutation subtype may be a clinically relevant factor and support further research on biomarker-driven treatment selection and the optimal sequencing of CDK4/6 inhibitors and PARP inhibitors in this population.

also in 111,027 other papers